{"id":"NCT03301649","sponsor":"Actavis Inc.","briefTitle":"Clinical Endpoint Study of Ivermectin 0.5% Lotion","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Lotion 0.5% (Actavis Laboratories UT, Inc.) to SKLICE® (Ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC) in the Treatment of Human Head Lice Infestation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-07","primaryCompletion":"2018-03-12","completion":"2018-03-12","firstPosted":"2017-10-04","resultsPosted":"2019-12-20","lastUpdate":"2019-12-20"},"enrollment":905,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Head Lice"],"interventions":[{"type":"DRUG","name":"Generic Ivermectin Lotion 0.5%","otherNames":[]},{"type":"DRUG","name":"Sklice® (Ivermectin) Lotion 0.5%","otherNames":[]},{"type":"DRUG","name":"Vehicle Lotion","otherNames":[]}],"arms":[{"label":"Generic Ivermectin Lotion 0.5%","type":"EXPERIMENTAL"},{"label":"Sklice (Ivermectin) Lotion 0.5%","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle Lotion","type":"PLACEBO_COMPARATOR"}],"summary":"This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo.","primaryOutcome":{"measure":"Percentage of Index Participants Who Were Considered a Treatment Success: PP Population","timeFrame":"Day 15 ± 2","effectByArm":[{"arm":"Generic Ivermectin Lotion 0.5%","deltaMin":90.9,"sd":null},{"arm":"Sklice (Ivermectin) Lotion","deltaMin":89,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM476999.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":399},"commonTop":["Application site pruritus","Headache","Eye irritation","Viral upper respiratory tract infection","Application site dysaesthesia"]}}